Corrigendum to "PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis" [EBioMedicine 40 (2019) 290-304]

Cristian Rodriguez-Aguayo,[a,b,1] Emine Bayraktar,[a,c,1] Cristina Ivan,[a,b] Burcu Aslan,[a,b] Junhua Mai,[d] Guangan He,[a] Lingegowda S. Mangala,[b,g] Dahai Jiang,[b,g] Archana S. Nagaraja,[g] Bulent Ozpolat,[a] Arturo Chavez-Reyes,[e] Mauro Ferrari,[d] Rahul Mitra,[b,g] Zahid H. Siddik,[a] Haifa Shen,[d] Xianbin Yang,[h] Anil K. Sood,[b,f,g] and Gabriel Lopez-Berestein [a,b,f,*]

[a]Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
[b]Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
[c]Department of Medical Biology, Faculty of Medicine, University of Gaziantep, Gaziantep 27310, Turkey
[d]Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA
[e]Centro de Investigación y Estudios Avanzados del IPN, Unidad Monterrey, Apodaca, NL, CP. 66600, Mexico
[f]Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
[g]Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
[h]AM Biotechnologies LLC, 12521 Gulf Freeway, Houston, TX 77034, USA

eBioMedicine 2022;83: 104194
Published online xxx
https://doi.org/10.1016/j.ebiom.2022.104194

The authors noticed that in Figure 6B, the TUNEL staining panel for the "PTGER3 siRNA" group was inadvertently duplicated in the next position for the group of "2'F-PS2-PTGER3 siRNA". Below is the corrected version of Figure 6B TUNEL staining panels with a new representative image for the 2'F-PS2-PTGER3 siRNA group. This change does not affect the results or conclusions.

The authors apologize for any inconvenience caused.



Figure 6B. Immunohistochemical analysis of Ki-67, CD-31, TUNEL and cisplatin uptake in mouse xenograft A2780-CP20 and OVCAR5 cisplatin-resistant tumors. The analysis showed that treatment with MSV-DOPC-PTGER3-siRNA or DOPC-2′-F-PS2-PTGER3 and/or combination with cisplatin reduced proliferation and angiogenesis and increased apoptosis in vivo. (A, B). Tumor tissue platinum uptake showed significantly greater accumulation of cisplatin in DOPC-PTGER3 siRNA and with greater uptake for DOPC-2′-F-PS2-PTGER3 in combination with cisplatin (C). Means ± SEM are shown. *, P b .05; **, P b .01; ***, P b .001. 302 C. Rodriguez-Aguayo et al. / EBioMedicine 40 (2019) 290-304.

DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2018.11.045
*Corresponding author.
E-mail address: glopez@mdanderson.org (G. Lopez-Berestein).

[1] These authors contributed equally to this work.